供氧与标准冷灌注在肾移植中的比较(COMPARE):随机双盲配对三期试验
COMPARE 试验在 19 个欧洲移植中心纳入循环死亡后捐献、年龄≥50 岁供者的 197 对肾脏,随机分配一侧肾脏接受供氧低温机器灌注(HMPO2)、对侧接受标准 HMP。
核心结论
- 循环死亡后捐献肾脏使用 HMPO2 是安全的,并减少移植后严重并发症(Clavien-Dindo IIIb 级及以上)。
- 12 个月 eGFR 在 HMPO2 与 HMP 组间无显著差异,但次要结局分析提示 HMPO2 可能有获益。
研究设计与样本
- 随机、双盲、配对、三期试验,在 19 个欧洲移植中心开展。
- 纳入循环死亡后捐献、年龄≥50 岁供者的肾脏对,且两肾均移植给不同受者。
- 每对供者肾脏随机分配一侧至 HMPO2、对侧至 HMP,灌注从器官获取维持至植入。
- 主要终点为随访结束时两移植肾均存活配对中 12 个月 eGFR(CKD-EPI 公式)。
- 2015 年 3 月 15 日至 2017 年 4 月 11 日随机 197 对肾脏,106 对移植入合格受者。
主要发现
- 23 对肾脏因肾衰竭或患者死亡被排除于主要分析。
临床怎么用
- 对循环死亡后捐献、年龄≥50 岁供者的肾脏,可考虑使用 HMPO2 以降低移植后严重并发症和移植物失败风险。
- HMPO2 对 12 个月 eGFR 的改善未达统计学显著,临床决策需结合次要结局获益综合评估。
局限性
- 主要分析排除了 23 对因肾衰竭或患者死亡未满足条件的肾脏对。
- 12 个月 eGFR 差异未达统计学显著,次要结局获益需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deceased donor kidneys are preserved in cold hypoxic conditions. Providing oxygen during preservation might improve post-transplant outcomes, particularly for kidneys subjected to greater degrees of preservation injury. This study aimed to investigate whether supplemental oxygen during hypothermic machine perfusion (HMP) could improve the outcome of kidneys donated after circulatory death. METHODS: This randomised, double-blind, paired, phase 3 trial was done in 19 European transplant centres. Kidney pairs from donors aged 50 years or older, donated after circulatory death, were eligible if both kidneys were transplanted into two different recipients. One kidney from each donor was randomly assigned using permuted blocks to oxygenated hypothermic machine perfusion (HMPO2), the other to HMP without oxygenation. Perfusion was maintained from organ retrieval to implantation. The primary outcome was 12-month estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equation in pairs of donated kidneys in which both transplanted kidneys were functioning at the end of follow-up. Safety outcomes were reported for all transplanted kidneys. Intention-to-treat analyses were done. This trial is registered with the ISRCTN Registry, ISRCTN32967929, and is now closed. FINDINGS: Between March 15, 2015, and April 11, 2017, 197 kidney pairs were randomised with 106 pairs transplanted into eligible recipients. 23 kidney pairs were excluded from the primary analysis because of kidney failure or patient death. Mean eGFR at 12 months was 50·5 mL/min per 1·73 m2 (SD 19·3) in the HMPO2 group versus 46·7 mL/min per 1·73m2 (17·1) in HMP (mean difference 3·7 mL/min per 1·73m2, 95% CI -1·0 to 8·4; p=0·12). Fewer severe complications (Clavien-Dindo grade IIIb or more) were reported in the HMPO2 group (46 of 417, 11%, 95% CI 8% to 14%) than in the HMP group (76 of 474, 16%, 13% to 20%; p=0·032). Graft failure was lower with HMPO2 (three [3%] of 106) compared with HMP (11 [10%] of 106; hazard ratio 0·27, 95% CI 0·07 to 0·95; p=0·028). INTERPRETATION: HMPO2 of kidneys donated after circulatory death is safe and reduces post-transplant complications (grade IIIb or more). The 12-month difference in eGFR between the HMPO2 and HMP groups was not significant when both kidneys from the same donor were still functioning 1-year post-transplant, but potential beneficial effects of HMPO2 were suggested by analysis of secondary outcomes. FUNDING: European Commission 7th Framework Programme.
引用
- Jochmans I, Brat A, Davies L, et al. Oxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomised, double-blind, paired, phase 3 trial. Lancet. 2020. PMID: 33220737. doi:10.1016/S0140-6736(20)32411-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。